Author(s)

Okonkwo N. Ogugua^1*, Hassan O. Adekunle¹, Gyasi E. Micheal², Oluyadi B. Fatai³, Ogunro Adunola³, Oderinlo Olufemi¹, Ulaikere Mildred³, Harriman Ayodele³

¹Eye Foundation Retina Institute, Lagos, Nigeria.
²Saint Thomas Eye Hospital, Accra, Ghana.
³Eye Foundation Hospital, Lagos, Nigeria.

Purpose: To report the significant worsening of Vitreomacular Traction (VMT), following the intravitreal injection of Bevacizumab (Avastin) in an Age Related Macular Degeneration (AMD) eye; thereby raising the awareness of this possibility. Method: Retrospective observational case report. Results: After 3 monthly doses of intravitreal injection of 1.25 mg/0.05 cc bevacizumab for treatment of AMD, a post injection OCT revealed the presence of VMT and an increased central macular thickness (CMT) by additional 268 microns compared to pre injection levels. Conclusion: Worsening of VMT and increase in CMT following injection of intravitreal drugs can occur. This VMT worsening effect of intravitreal injections is under recognized. It demands greater attention since it is seen with a new common route of ocular drug delivery and may be responsible for cases of pharmacological failure.

Vitreomacular Traction, Vitreomacular Adhesion, Intravitreal Injection, Optical Coherence Tomography, Avastin, Age Related Macular Degeneration

Ogugua, O. , Adekunle, H. , Micheal, G. , Fatai, O. , Adunola, O. , Olufemi, O. , Mildred, U. and Ayodele, H. (2017) Vitreomacular Traction Post Intravitreal Bevacizumab for Age Related Macular Degeneration. Open Journal of Ophthalmology, 7, 138-144. doi: 10.4236/ojoph.2017.72019.